Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.54 |
| ▸ | NQO2 | P16083 | 7/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7395768 | 0.85 | GAA (0.54) | GAASLC9A1NQO2ABL1KDM4E | |
| SCHEMBL25988894 | 0.82 | RXFP1 (0.50) | GAASLC9A1NQO2ABL1KDM4E | |
| SCHEMBL29923806 | 0.81 | CFTR (0.47) | GAANQO2ABL1KDM4EALDH1A1 | |
| SCHEMBL23605399 | 0.81 | ABL1 (0.51) | GAANQO2ABL1KDM4EALDH1A1 | |
| SCHEMBL25988890 | 0.80 | GAA (0.46) | GAANQO2ABL1KDM4EALDH1A1 | |
| SCHEMBL19037342 | 0.79 | KDM4E (0.47) | GAANQO2ABL1KDM4EALDH1A1 | |
| SCHEMBL27801681 | 0.79 | ALDH1A1 (0.48) | GAANQO2ABL1KDM4EALDH1A1 | |
| SCHEMBL30843967 | 0.78 | KEAP1 (0.49) | GAANQO2ABL1KDM4EALDH1A1 | |
| SCHEMBL27235549 | 0.78 | KEAP1 (0.49) | GAANQO2ABL1KDM4EALDH1A1 | |
| SCHEMBL23674344 | 0.77 | SLC9A1 (0.61) | SLC9A1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108442-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-04-06 | — | — | US | disclosed |
| US-7012080-B2 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1620435-A1 | IMADAZOPYRIDINE COMPOUNDS HAVING 5-HT sb 4 /sb RECEPTOR AGONISTIC ACTIVITY AND 5-HT sb 3 /sb RECEPTOR ANTAGONISTIC ACTIVITY | PFIZER INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1440071-B1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS | PFIZER (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6951867-B2 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1543005-A1 | IMIDAZOPYRIDINE COMPUNDS AS 5-HT4 RECEPTOR AGONISTS | PFIZER INC. (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1543004-A1 | N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER INC. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040266814-A1 | Imidazopyridine compounds having 5-HT4 receptor agonistic activity and 5-HT3 receptor antagonistic activity | PFIZER INC | 2004-12-30 | — | — | US | disclosed |
| WO-2004094418-A1 | IMIDAZOPYRIDINE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY AND 5-HT3 RECEPTOR ANTAGONISTIC ACTIVITY | PFIZER INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1440071-A1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS | Pfizer Japan Inc. (JP) | 2004-07-28 | — | — | EP | disclosed |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2004-07-01 | — | — | US | disclosed |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
| WO-2004026869-A1 | IMIDAZOPYRIDINE COMPUNDS AS 5-HT4 RECEPTOR AGONISTS | PFIZER JAPAN INC. (JP) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026868-A1 | N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2004-04-01 | — | — | WO | disclosed |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | UCHIDA CHIKARA (JP) | 2004-02-19 | — | — | US | disclosed |
| US-6624162-B2 | 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. | PFIZER INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003035649-A1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | GAA 3781/4885SLC9A1 268/4885NQO2 1768/4885 |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | GAA 3732/4885SLC9A1 334/4885NQO2 2362/4885 |
| US-20230108442-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | QDPR, DHODH, THPO | GAA 1943/4885SLC9A1 1923/4885NQO2 177/4885 |
| US-20040266814-A1 | Imidazopyridine compounds having 5-HT4 receptor agonistic activity and 5-HT3 receptor antagonistic activity | HTR4, HRH4, GIPR | GAA 3755/4885SLC9A1 1038/4885NQO2 4055/4885 |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | HTR4, GPR4, HRH4 | GAA 3990/4885SLC9A1 496/4885NQO2 3480/4885 |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HRH4, HTR4, HRH2 | GAA 3701/4885SLC9A1 276/4885NQO2 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.